Adaptive COVID-19 Treatment Trial in the EU & UK (ACTT-EU/UK) - A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults
Safety and treatment success of treatments for patients unwell, and hospitalised, with COVID-19.
What is this study about?
In the initial phase of this study we would like to make sure that remdesivir, a drug originally developed for the treatment of Ebola virus, is safe for use in humans with COVID-19, and see if it can improve patients’ health when they are sick and hospitalised, with COVID-19.
It is a multi arm, adaptive study so as new treatments evolve, we hope to include these as treatment randomisations within the trial.
Type of study
Who is funding the study?
Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases, National Institutes of Health USA
When is it taking place?
April 2020 - April 2023
Where is it taking place?
International trial; initially USA, Japan, South Korea, Denmark, Germany, Greece and the UK but plan to open in Spain, Italy and other EU countries
Who is included?
Hospitalised, non-pregnant adults (18 years or older) with confirmed COVID-19
MRC CTU at UCL response to COVID-19 pandemic
26 Mar 2020